Forging a New Frontier: Antimicrobial Peptides and Nanotechnology Converging to Conquer Gastrointestinal Pathogens

Area of Science:

• Microbiology
• Nanotechnology
• Pharmacology

Background:

• Gastrointestinal infections caused by pathogenic bacteria present a significant global health challenge.
• Conventional therapies are often ineffective due to physical, biological, and biopharmaceutical barriers, leading to multidrug-resistant strains and dysbiosis.
• Antibiotic overuse further exacerbates resistance and negatively impacts gut microbiota.

Purpose of the Study:

• To review the application of nanotechnology in enhancing antimicrobial peptides (AMPs) for treating gastrointestinal infections.
• To evaluate the efficacy of various nanocarriers loaded with AMPs against intestinal pathogens.
• To highlight the potential of nanotech-AMPs in overcoming limitations of traditional therapies.

Main Methods:

• Critical review of existing literature on nanotechnology-based antimicrobial peptide delivery systems.
• Evaluation of in vitro and in vivo studies assessing the efficacy of nanocarrier-encapsulated AMPs.
• Analysis of factors influencing AMP stability, targeted delivery, and therapeutic outcomes.

Main Results:

• Nanotechnology offers a promising strategy to improve AMP stability and achieve targeted delivery to the gastrointestinal tract.
• Various nanocarriers have demonstrated efficacy in vitro and in vivo against intestinal pathogens.
• Nanotechnology can help overcome challenges such as low bioavailability and resistance associated with conventional treatments.

Conclusions:

• Nanotechnology-based delivery systems represent a significant advancement in managing gastrointestinal infections.
• Further research into the encapsulation and functionalization of AMPs is crucial for their clinical translation.
• This approach holds the potential to revolutionize the global control of intestinal bacterial infections.